ArticleCancer cell international2025
Bifidobacterium enhances the antitumor efficacy of carboplatin in glioblastoma cells: targeting apoptotic and cell cycle regulatory pathways via Caspase, AKT/PTEN, and P53/P21 signaling.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Synergistic Anti-Lung Cancer Effects of Cytarabine and a NCBI-RegisteredFood science & nutrition · 2026Article
- Molecular and Immunological Mechanisms Underlying the Anticancer Effects of Bifidobacterium.Probiotics and antimicrobial proteins · 2026Review
- Case Report: Fecal microbiota transplantation resensitizes advanced non-small cell lung cancer to platinum-based chemotherapy.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma multiforme (GBM) is an aggressive brain tumor with poor response to chemotherapy such as Carboplatin, mainly due to drug resistance and systemic toxicity. Recent studies suggest that probiotics like Bifidobacterium reuteri may have anti-tumor properties and enhance the efficacy of chemotherapy. This study evaluates the potential of B. reuteri Ab.338 SH (GenBank: PV961363), isolated from traditional yogurt, in potentiating Carboplatin's effects on U-87 MG glioblastoma cells.
methodsB. reuteri Ab.338 SH was isolated and molecularly characterized. U-87 MG cells were treated with Carboplatin, B. reuteri, and their combination. Cell viability was evaluated by MTT assay, apoptosis by Annexin V-FITC/PI staining and flow cytometry, and gene expression of apoptosis-related markers by qRT-PCR. Selectivity was confirmed using HUVEC cells as a normal control.
resultsT treatment markedly reduced the effective dose of Carboplatin and enhanced apoptosis compared with either treatment alone. Flow cytometry showed increased late apoptotic cells with co-treatment. qRT-PCR analysis revealed upregulation of pro-apoptotic genes (he combinationBAX, Caspase-3/8/9, Fas, PTEN, IκB, P53, P21) and downregulation of AKT, mTOR, and Bcl-2. B. reuteri alone showed no cytotoxicity toward normal endothelial cells.
conclusionB. reuteri Ab.338 SH enhances Carboplatin efficacy in GBM cells while lowering its required dose and potential toxicity. This probiotic may serve as a promising adjuvant in GBM therapy, warranting further in vivo validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.